MEDICLIN AG (MED.DE) Fundamental Analysis & Valuation

FRA:MED • DE0006595101

Current stock price

3.46 EUR
-0.14 (-3.89%)
Last:

This MED.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MED.DE Profitability Analysis

1.1 Basic Checks

  • MED had positive earnings in the past year.
  • In the past year MED had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
  • Each year in the past 5 years MED had a positive operating cash flow.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

1.2 Ratios

  • With a decent Return On Assets value of 3.85%, MED is doing good in the industry, outperforming 75.76% of the companies in the same industry.
  • The Return On Equity of MED (14.15%) is better than 84.85% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.06%, MED is in the better half of the industry, outperforming 75.76% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.44%.
  • The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROIC 7.06%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

1.3 Margins

  • The Profit Margin of MED (4.40%) is better than 66.67% of its industry peers.
  • MED's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.52%, MED is in the better half of the industry, outperforming 60.61% of the companies in the same industry.
  • MED's Operating Margin has improved in the last couple of years.
  • MED has a Gross Margin of 84.08%. This is amongst the best in the industry. MED outperforms 87.88% of its industry peers.
  • In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MED.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
  • Compared to 1 year ago, MED has about the same amount of shares outstanding.
  • MED has about the same amout of shares outstanding than it did 5 years ago.
  • MED has a better debt/assets ratio than last year.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.59, we must say that MED is in the distress zone and has some risk of bankruptcy.
  • MED has a Altman-Z score of 1.59. This is comparable to the rest of the industry: MED outperforms 42.42% of its industry peers.
  • The Debt to FCF ratio of MED is 9.63, which is on the high side as it means it would take MED, 9.63 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of MED (9.63) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
  • MED's Debt to Equity ratio of 1.69 is on the low side compared to the rest of the industry. MED is outperformed by 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Altman-Z 1.59
ROIC/WACC1.36
WACC5.18%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
  • MED has a Current ratio of 1.93. This is amongst the best in the industry. MED outperforms 84.85% of its industry peers.
  • A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.89, MED belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.89
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MED.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 414.18% over the past year.
  • Measured over the past years, MED shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.79% on average per year.
  • Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 3.40% in the last year.
  • MED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.19% yearly.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.30% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 3.41% on average over the next years.
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

9

4. MED.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.68, which indicates a rather cheap valuation of MED.
  • MED's Price/Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of MED to the average of the S&P500 Index (25.71), we can say MED is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 4.63, the valuation of MED can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 100.00% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of MED to the average of the S&P500 Index (23.83), we can say MED is valued rather cheaply.
Industry RankSector Rank
PE 4.68
Fwd PE 4.63
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MED is valued cheaply inside the industry as 96.97% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, MED is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.53
EV/EBITDA 2.84
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MED has a very decent profitability rating, which may justify a higher PE ratio.
  • MED's earnings are expected to grow with 22.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.06
PEG (5Y)0.22
EPS Next 2Y34.35%
EPS Next 3Y22.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. MED.DE Dividend Analysis

5.1 Amount

  • MED has a Yearly Dividend Yield of 1.17%.
  • MED's Dividend Yield is comparable with the industry average which is at 1.69.
  • Compared to the average S&P500 Dividend Yield of 1.91, MED is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.17%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MED.DE Yearly Dividends per shareMED.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 0.01 0.02 0.03 0.04

5.3 Sustainability

DPN/A
EPS Next 2Y34.35%
EPS Next 3Y22.3%
MED.DE Yearly Income VS Free CF VS DividendMED.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

More info and screens

Find the best dividend stocksShow peers with best dividend

MED.DE Fundamentals: All Metrics, Ratios and Statistics

MEDICLIN AG

FRA:MED (3/16/2026, 4:04:06 PM)

3.46

-0.14 (-3.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04
Earnings (Next)03-26
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap164.35M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (69.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.17%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)9.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
Industry RankSector Rank
PE 4.68
Fwd PE 4.63
P/S 0.21
P/FCF 3.53
P/OCF 1.7
P/B 0.66
P/tB 0.74
EV/EBITDA 2.84
EPS(TTM)0.74
EY21.39%
EPS(NY)0.75
Fwd EY21.6%
FCF(TTM)0.98
FCFY28.29%
OCF(TTM)2.04
OCFY58.82%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.06
PEG (5Y)0.22
Graham Number9.32
Profitability
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROCE 9.1%
ROIC 7.06%
ROICexc 9.61%
ROICexgc 10.05%
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
FCFM 5.83%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Debt/EBITDA 3.49
Cap/Depr 96.09%
Cap/Sales 6.29%
Interest Coverage 3.18
Cash Conversion 80.47%
Profit Quality 132.66%
Current Ratio 1.93
Quick Ratio 1.89
Altman-Z 1.59
F-Score8
WACC5.18%
ROIC/WACC1.36
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%

MEDICLIN AG / MED.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.


Can you provide the valuation status for MEDICLIN AG?

ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.


Can you provide the profitability details for MEDICLIN AG?

MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for MED stock?

The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 4.68 and the Price/Book (PB) ratio is 0.66.


What is the financial health of MEDICLIN AG (MED.DE) stock?

The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.